Pages that link to "Q54395043"
Jump to navigation
Jump to search
The following pages link to Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. (Q54395043):
Displaying 31 items.
- Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspective (Q27009221) (← links)
- Voriconazole metabolism, toxicity, and the effect of cytochrome P450 2C19 genotype (Q33684379) (← links)
- CYP2C19 polymorphisms and therapeutic drug monitoring of voriconazole: are we ready for clinical implementation of pharmacogenomics? (Q33849298) (← links)
- Variability of voriconazole plasma concentrations after allogeneic hematopoietic stem cell transplantation: impact of cytochrome p450 polymorphisms and comedications on initial and subsequent trough levels (Q35169112) (← links)
- In vitro study of the variable effects of proton pump inhibitors on voriconazole (Q35960842) (← links)
- A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine (Q36088030) (← links)
- Budget impact analysis of CYP2C19-guided voriconazole prophylaxis in AML. (Q36185299) (← links)
- Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole (Q36608562) (← links)
- Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events (Q36849416) (← links)
- Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring (Q36927577) (← links)
- Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies (Q36969780) (← links)
- Pharmacogenomics of the triazole antifungal agent voriconazole (Q37892536) (← links)
- Has the era of individualised medicine arrived for antifungals? A review of antifungal pharmacogenomics. (Q37904672) (← links)
- Therapeutic Drug Monitoring of Voriconazole in Children (Q37972513) (← links)
- Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014. (Q38284468) (← links)
- Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach (Q38362057) (← links)
- Therapeutic Drug Monitoring of Voriconazole in the Management of Invasive Fungal Infections: A Critical Review. (Q38526795) (← links)
- Different effects of lansoprazole and rabeprazole on the plasma voriconazole trough levels in allogeneic hematopoietic cell transplant recipients. (Q39479653) (← links)
- Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections (Q40290020) (← links)
- Impact of CYP2C19 Polymorphisms on Serum Concentration of Voriconazole in Iranian Hematological Patients (Q42269872) (← links)
- Pharmacogenetics and beyond: variability of voriconazole plasma levels in a patient with primary immunodeficiency (Q42283754) (← links)
- Interaction of ambrisentan with clarithromycin and its modulation by polymorphic SLCO1B1. (Q42710782) (← links)
- High metabolic N-oxidation of voriconazole in a patient with refractory aspergillosis and CYP2C19*17/*17 genotype. (Q43232273) (← links)
- Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole. (Q47425844) (← links)
- The effect of induction of CYP3A4 by St John's wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype (Q47803945) (← links)
- Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing (Q51110220) (← links)
- Value of Supportive Care Pharmacogenomics in Oncology Practice. (Q52603826) (← links)
- Evaluation of CYP2C19 Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant (Q90248380) (← links)
- Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers (Q92454707) (← links)
- High-Resolution Melting Assay for Genotyping Variants of the CYP2C19 Enzyme and Predicting Voriconazole Effectiveness (Q92613671) (← links)
- Development and validation of T-ARMS-PCR to detect CYP2C19*17 allele (Q92806588) (← links)